- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Regeneron Pharmaceuticals Inc
+ Add to WatchlistREGN:US
242.760 USD 10.050 4.32%As of 20:10:00 ET on 06/18/2013.
Snapshot for Regeneron Pharmaceuticals Inc (REGN)
| Open: | 233.640 | Day's Range: | 230.510 - 244.260 | Volume: | 888,757 |
|---|---|---|---|---|---|
| Previous Close: | 232.710 | 52wk Range: | 107.310 - 283.989 | 1-Yr Rtn: | +109.29% |
Key Statistics for REGN
| Current P/E Ratio (ttm) | 32.8054 |
|---|---|
| Estimated P/E(12/2013) | 37.9076 |
| Relative P/E vs. SPX | 2.0312 |
| Earnings Per Share (USD) (ttm) | 7.4000 |
| Est. EPS (USD) (12/2013) | 6.4040 |
| Est. PEG Ratio | 1.5121 |
| Market Cap (M USD) | 23,794.75 |
| Shares Outstanding (M) | 95.91 |
| 30 Day Average Volume | 794,372 |
| Price/Book (mrq) | 16.8662 |
| Price/Sale (ttm) | 14.6324 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for REGN
Company Profile & Key Executives for REGN
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
| Leonard S Schleifer "Len"President/CEO/Co-Founder | George D YancopoulosPres:Regeneron Laboratories |
| Murray A GoldbergSenior VP/CFO/Treasurer/Asst Secy | Joseph J Larosa "Joe"Senior VP/Secy/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
REGN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page